Shridar Ganesan, MD, PhD, section chief, Molecular Oncology, associate director, Translational Science, Omar Boraie Chair, Genomic Science, professor, medicine, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses the current limitations and advantages of leveraging circulating-tumor DNA (ctDNA) to detect minimal residual disease (MRD) in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice. Watch more at onclive.com.
onclive.com